Oncology
Rybrevant Faspro · head and neck cancer
Accelerated approval · As of
OrigAMI-4 examined amivantamab in head and neck cancer. FDA based the new indication on a group of 102 previously treated patients.
Milestone history
OrigAMI-4 (NCT06385080) began.
ClinicalTrials.govFDA granted accelerated approval for eligible adults with recurrent or metastatic disease after platinum and PD-(L)1 therapy.
FDA